Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - desvenlafaxine benzoate, quantity: 146.32 mg (equivalent: desvenlafaxine, qty 100 mg) - tablet, modified release - excipient ingredients: hypromellose; colloidal anhydrous silica; purified talc; microcrystalline cellulose; stearic acid; titanium dioxide; sunset yellow fcf aluminium lake; iron oxide red; polyvinyl alcohol; macrogol 3350 - desvenlafaxine is indicated for the treatment of major depressive disorder, including the prevention of relapse.,desvenlafaxine is not indicated for paediatric use.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - desvenlafaxine benzoate, quantity: 73.16 mg (equivalent: desvenlafaxine, qty 50 mg) - tablet, modified release - excipient ingredients: hypromellose; colloidal anhydrous silica; purified talc; microcrystalline cellulose; stearic acid; titanium dioxide; iron oxide yellow; iron oxide red; polyvinyl alcohol; macrogol 3350 - desvenlafaxine is indicated for the treatment of major depressive disorder, including the prevention of relapse.,desvenlafaxine is not indicated for paediatric use.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

qiagen pty ltd - ct929 - acquired genetic alteration ivds - the therascreen pik3ca rgq pcr kit is intended for use as a companion diagnostic test, to aid clinicians in identification of breast cancer patients who may be eligible for treatment with piqray (alpelisib) based on a pik3ca mutation detected result.

Austràlia - anglès - APVMA (Australian Pesticides and Veterinary Medicines Authority)

fosterra pty ltd - mcpa present as the iso octyl ester - emulsifiable concentrate - mcpa present as the iso octyl ester phenoxy acids-mcpa-ester active 500.0 g/l - herbicide - barley | cereal rye | grass pasture | oats | pasture grass seed crop | triticale | wheat - bathurst burr | capeweed | charlock | dandelion - taraxacum officinale | fat hen | fumitory | hedge or wild mustard | lincoln weed, sand rocket or mustard | london rocket | noogoora burr | paterson's curse | saffron thistle | scotch thistle | skeleton weed | slender, shore or sheep thistle | spear or black thistle | stinkwort | turnip weed | variegated thistle | volunteer canola or rapeseed | volunteer safflower | volunteer sunflower | wild radish or radish weed | wild sage | wild turnip | blessed thistle | brassica campestris | brassica kaber | brassica rapa ssp. sylvestris | brassica rapa var. sylvestris | brassica sinapistrum | bull thistle | cabbage thistle | carduus marianus | cockleburr | common dandelion | cotton thistle | crambling mustard | echium lycopsis | echium spp. | english dandelion | european dandelion | false star thistle | giant mustard | hedge mustard | heraldic thistle | holy thistle | jointed charlock | lady's thistle | milk thistle | pink weed | purple bugloss | purple viper's bugloss |

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - rivaroxaban, quantity: 10 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; sodium lauryl sulfate; croscarmellose sodium; hypromellose; lactose monohydrate; iron oxide red; titanium dioxide; macrogol 3350; magnesium stearate - xarelto is indicated for: ? prevention of venous thromboembolism (vte) in adult patients who have undergone major orthopaedic surgery of the lower limbs (elective total hip replacement, treatment for up to 5 weeks; elective total knee replacement, treatment for up to 2 weeks) ? prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation and at least one additional risk factor for stroke ? treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe) and for the prevention of recurrent dvt and pe,xarelto, in combination with aspirin, is indicated for ? the prevention of major cardiovascular events (composite of stroke, myocardial infarction and cardiovascular death) in patients with coronary artery disease (cad) and/or peripheral artery disease (pad).

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - rivaroxaban, quantity: 20 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; croscarmellose sodium; hypromellose; lactose monohydrate; magnesium stearate; sodium lauryl sulfate; iron oxide red; macrogol 3350; titanium dioxide - xarelto is indicated for: ? prevention of venous thromboembolism (vte) in adult patients who have undergone major orthopaedic surgery of the lower limbs (elective total hip replacement, treatment for up to 5 weeks; elective total knee replacement, treatment for up to 2 weeks) ? prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation and at least one additional risk factor for stroke ? treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe) and for the prevention of recurrent dvt and pe,xarelto, in combination with aspirin, is indicated for ? the prevention of major cardiovascular events (composite of stroke, myocardial infarction and cardiovascular death) in patients with coronary artery disease (cad) and/or peripheral artery disease (pad).

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - rivaroxaban, quantity: 15 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; croscarmellose sodium; hypromellose; lactose monohydrate; magnesium stearate; sodium lauryl sulfate; iron oxide red; macrogol 3350; titanium dioxide - xarelto is indicated for: ? prevention of venous thromboembolism (vte) in adult patients who have undergone major orthopaedic surgery of the lower limbs (elective total hip replacement, treatment for up to 5 weeks; elective total knee replacement, treatment for up to 2 weeks) ? prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation and at least one additional risk factor for stroke ? treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe) and for the prevention of recurrent dvt and pe,xarelto, in combination with aspirin, is indicated for ? the prevention of major cardiovascular events (composite of stroke, myocardial infarction and cardiovascular death) in patients with coronary artery disease (cad) and/or peripheral artery disease (pad).

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - rivaroxaban, quantity: 2.5 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; croscarmellose sodium; hypromellose; lactose monohydrate; magnesium stearate; sodium lauryl sulfate; macrogol 3350; titanium dioxide; propylene glycol; purified talc; iron oxide yellow; macrogol 6000 - xarelto is indicated for: ? prevention of venous thromboembolism (vte) in adult patients who have undergone major orthopaedic surgery of the lower limbs (elective total hip replacement, treatment for up to 5 weeks; elective total knee replacement, treatment for up to 2 weeks) ? prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation and at least one additional risk factor for stroke ? treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe) and for the prevention of recurrent dvt and pe,xarelto, in combination with aspirin, is indicated for ? the prevention of major cardiovascular events (composite of stroke, myocardial infarction and cardiovascular death) in patients with coronary artery disease (cad) and/or peripheral artery disease (pad).

Israel - anglès - Ministry of Health

bayer israel ltd - rivaroxaban - film coated tablets - rivaroxaban 2.5 mg - rivaroxaban - xarelto, co-administered with acetylsalicylic acid (asa) alone or with asa plus clopidogrel , is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (acs) with elevated cardiac biomarkers.xarelto, co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events.

Canadà - anglès - Health Canada

novartis pharmaceuticals canada inc - alpelisib - tablet - 50mg - alpelisib 50mg - antineoplastic agents